Skip to main content
GENESIS IBRC INDIA LIMITED logo

GENESIS IBRC INDIA LIMITED — Investor Relations & Filings

Ticker · 514336 ISIN · INE194N01016 BSE.NS Manufacturing
Filings indexed 311 across all filing types
Latest filing 2023-05-22 Regulatory Filings
Country IN India
Listing BSE.NS 514336

About GENESIS IBRC INDIA LIMITED

https://genesisiil.com/

Genesis IBRC India Limited is a biotechnology-driven enterprise focused on the research, development, and commercialization of advanced biological solutions. The company specializes in the production of high-quality probiotics and industrial enzymes tailored for diverse applications. Its product portfolio serves critical sectors including aquaculture, poultry, animal husbandry, and human nutrition, providing microbial formulations designed to enhance growth, immunity, and overall health. In the industrial segment, the company develops enzymatic solutions for the textile, leather, and paper processing sectors to improve efficiency and environmental sustainability. Genesis IBRC emphasizes innovation through its dedicated research facilities, focusing on strain selection and fermentation technology to deliver standardized and effective biochemical products. The company aims to provide science-based alternatives to traditional chemical processes across global markets.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 23(9) of SEBI (LODR) Regulations, 2015, we hereby submit the disclosure on Related Party Transactions for the Half Year ended 31st March, 2023 in the format as prescribed ....
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically detailing Related Party Transactions for the half year ended March 31, 2023. It is a regulatory compliance filing providing details of related party transactions, not a full financial report or audit report. The document length is short (2052 characters) and it is a formal disclosure to the stock exchange (BSE Limited). This fits the category of Regulatory Filings (RNS) as it is a compliance disclosure that does not contain comprehensive financial statements or management discussion but is a regulatory announcement.
2023-05-22 English
please find enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015: 1. Audited Financial Results for the Fourth Quarter and Financial ....
Regulatory Filings
2023-05-22 English
We would like to inform you that the Board of Directors of the Company, in their just concluded meeting have, inter alia, transacted the following items of business: 1. Approved ....
Regulatory Filings Classification · 95% confidence The document is a short announcement from the company informing about the outcome of a Board Meeting. It states that the Board approved the audited financial results for the quarter and year ended March 31, 2023, and mentions the auditor's report. However, the document itself does not contain the full audited financial results or detailed financial statements; it only announces the approval and outcome. The length is only 1389 characters, which is quite short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about the board meeting outcome and financial results approval without the full report attached.
2023-05-22 English
Genesis Ibrc India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2023 ,inter alia, to consider and approve 1. Statement of Audited ....
Regulatory Filings Classification · 95% confidence The document is a notice from Genesis IBRC India Limited informing the stock exchange (BSE Limited) about an upcoming Board Meeting scheduled for 22 May 2023. The purpose of the meeting is to consider and approve the audited financial results for the quarter and financial year ended 31 March 2023, as well as the financial statements for the year ended 31 March 2023. The document references SEBI Listing Obligations and Disclosure Requirements Regulations, indicating a regulatory compliance announcement. The document is short (1622 characters) and serves as a notification of a future event (Board Meeting) rather than containing the actual financial results or statements. It does not contain financial data or detailed reports itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement informing about the Board Meeting and upcoming financial results approval, not the report itself or a detailed management discussion.
2023-05-13 English
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the ....
Board/Management Information Classification · 100% confidence The document is a notification about the outcome of a board meeting, specifically announcing the appointment of a new Company Secretary and Compliance Officer. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and includes details as per SEBI Circular No. CIR/CFD/CMD/4/2015. The content is focused on management change rather than financial results, audit, or other report types. The document length is short (2648 characters) and it is an announcement rather than a full report. Therefore, it fits the category of Board/Management Information (MANG).
2023-04-28 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings
2023-04-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.